Dinaciclib Combination To Be Tested In Multiple Myeloma Clinical Trial
Researchers from the U.S. National Cancer Institute recently initiated a Phase 1 clinical trial that will test whether dinaciclib in combination with Velcade and dexamethasone is safe and effective as an anti-myeloma therapy.
The clinical trial is taking place at a several locations across the United States, and is open to multiple myeloma patients who have relapsed after at least one previous myeloma treatment regimen.
Dinaciclib (SCH727965) is currently being developed by Merck (NYSE: MRK). It is a small molecule that inhibits enzymes called cyclin-dependent kinases, which regulate the cell cycle and are often overactive in cancer cells. Dinaciclib interrupts the cell cycle by inhibiting these kinases, ultimately causing the cell to die.
Preclinical studies have shown that Velcade (bortezomib) is more effective when cyclin-dependent kinases are inhibited, and a previous Phase 1/2 study showed that dinaciclib is safe and active as a monotherapy for relapsed/refractory myeloma (see related Beacon news).
Therefore, this study is being conducted to determine the efficacy and safety of dinaciclib in combination with Velcade and dexamethasone (Decadron).
For more information about the trial, see the trial description at the U.S. clinical trial registry.
Related Articles:
- None Found
It is great that this and other recent research in MM therapy is studying various innovative mechanisms in combination with the recognized benefits of Imib's, proteasome inhibitors and steroids. The monoclonal antibodies for immunotherapy appear to be the most promising, and likely will be the next class of drugs to be FDA approved for MM therapy. But researchers benefit from thinking outside the box. A breakthrough therapy using new classes of pharmaceuticals is certainly possible. May that be so soon!
After a quick look at the results of the single agent study, this appears to be an interesting trial. Here is hoping that is works in tandem with Velcade and proves to be a great combo.
Get new Myeloma Beacon articles by email.